ArticleLeukemia2018

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.

I S Jerchel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.